Elsevier eBooks, Год журнала: 2024, Номер unknown
Опубликована: Янв. 1, 2024
Язык: Английский
Journal of Cancer, Год журнала: 2024, Номер 15(7), С. 2024 - 2032
Опубликована: Янв. 1, 2024
Objective: This study evaluated the efficacy and safety of gemcitabine oxaliplatin intrathoracic perfusion chemotherapy (IPCGOR) regimen combined with interleukin-2 (IL-2) for advanced non-small cell lung cancer (NSCLC).Methods: We conducted a retrospective analysis 460 NSCLC patients from Yunnan Province Early Cancer Diagnosis Treatment Project (June 2020-October 2022), assessing IPCGOR IL-2 combination.Outcomes were measured based on RECIST 1.1 criteria, focusing objective response rate (ORR), disease control (DCR), median progression-free survival (mPFS), overall (MOS), treatment safety.Results: The demonstrated an ORR 67.4%, DCR 97.4%, mPFS 8.5 months, MOS 12.5 months.14 underwent successful surgery post-treatment.Common adverse reactions manageable, no treatment-related deaths reported. Conclusion:The shows promising tolerable profile NSCLC.These findings suggest its potential as reference treating NSCLC.However, study's nature single-center design pose limitations.Future research should focus prospective studies, randomized controlled trials, long-term outcome assessments, particularly in diverse patient subgroups, to further validate refine clinical application this regimen.
Язык: Английский
Процитировано
17
Journal of Clinical Medicine, Год журнала: 2024, Номер 13(7), С. 2046 - 2046
Опубликована: Апрель 1, 2024
Over the past two decades, prognosis in adolescents and young adults (AYAs) diagnosed with acute myeloid leukemia (AML) has significantly improved. The standard intensive cytotoxic treatment approach for AYAs AML, consisting of induction chemotherapy anthracycline/cytarabine combination followed by consolidation or stem cell transplantation, lately been shifting toward novel targeted therapies, mostly fields clinical trials. One most recent advances treating AML is B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax hypomethylating agents, which studied elderly populations was approved Food Drug Administration (FDA) patients over 75 years age excluded from schemas due to comorbidities. Regarding AYA population, therapy could be a therapeutic option refractory/relapsed (R/R) although data real-world studies are currently limited. Venetoclax frequently used advanced hematologic malignancies, mainly lymphoblastic myelodysplastic syndromes, as salvage considerable efficacy safety. Herein, we aim summarize evidence obtained trials observational on use AML. Based available evidence, safe effective R/R patients. However, further research larger cohorts needed confirm these data, establishing benefits venetoclax-based regimen this special population.
Язык: Английский
Процитировано
5
Critical Reviews in Oncology/Hematology, Год журнала: 2024, Номер 201, С. 104438 - 104438
Опубликована: Июль 6, 2024
Язык: Английский
Процитировано
5
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(17), С. 9143 - 9143
Опубликована: Авг. 23, 2024
Besides producing cellular energy, mitochondria are crucial in controlling oxidative stress and modulating metabolism, particularly under stressful conditions. A key aspect of this regulatory role involves the recycling process autophagy, which helps to sustain energy homeostasis. Autophagy, a lysosome-dependent degradation pathway, plays fundamental maintaining homeostasis by degrading damaged organelles misfolded proteins. In context tumor formation, autophagy significantly influences cancer metabolism chemotherapy resistance, contributing both suppression surveillance. This review focuses on relationship between specifically progression. Investigating interaction reveals new possibilities for treatments may result development more effective therapies targeting mitochondria, could have significant implications treatment. Additionally, highlights increasing understanding autophagy’s development, with focus mitochondrial function pre-clinical clinical research. It also explores potential developing more-targeted personalized investigating autophagy-related biomarkers.
Язык: Английский
Процитировано
3
Frontiers in Neuroscience, Год журнала: 2025, Номер 18
Опубликована: Янв. 15, 2025
Intracerebral hemorrhage (ICH) is a major public health challenge worldwide, and associated with elevated rates of mortality, disability, morbidity, especially in low- middle-income nations. However, our knowledge the detailed molecular processes involved ICH remains insufficient, particularly those secondary injury stage, resulting lack effective treatments for ICH. Human platelet lysates (HPL) are abundant bioactive factors, numerous studies have demonstrated their beneficial effects on neurological diseases, including anti-neuroinflammatory ability, anti-oxidant effects, maintenance blood-brain barrier integrity, promotion neurogenesis. In this review, we thoroughly explore potential HPL treating from three critical perspectives: rationale selecting as treatment ICH, mechanisms through which contributes to management, additional measures necessary We elucidate role platelets pathophysiology highlight limitations current options advancements preclinical research application disorders. Furthermore, historical developments preparation methods field biomedicine discussed. Additionally, summarize molecules present therapeutic Finally, outline issues that must be addressed regarding utilizing modality
Язык: Английский
Процитировано
0
Опубликована: Янв. 9, 2025
Objective: This study investigates the development trends and research hotspots in clinical testing for multiple myeloma from 2000 to 2023, using bibliometric techniques. Method: Search relevant literature on of published Web Science Core Collection (WoSCC) use CiteSpace 6.2.R4 software draw a visual knowledge map authors, institutions, national regional cooperation networks, journals, keywords, conduct analysis. Results: The found an upward trend publications over specified period, with significant growth noted 2012 onwards. majority originates United States, contributions institutions like Mayo Clinic MD Anderson Cancer Center. Analysis author collaboration networks indicated relatively low centrality, suggesting minimal among researchers. Bibliometric mapping highlighted several field including therapeutic strategies involving proteasome inhibitors immunomodulatory drugs, role stem cell transplantation, importance achieving monitoring residual disease. Conclusion: is characterized by growing body research, States. Despite increasing volume there need enhanced researchers consolidate findings advance practice.
Язык: Английский
Процитировано
0
Frontiers in Oncology, Год журнала: 2025, Номер 14
Опубликована: Янв. 21, 2025
Apoptosis is an essential characteristic of cancer and its dysregular promotes tumor growth, clonal evolution, treatment resistance. B-cell lymphoma-2 (BCL-2) protein family members are key to the intrinsic, mitochondrial apoptotic pathway. The inhibition BCL-2 pro-survival proteins, which frequently overexpressed in malignancies pose a fundamental carcinogenic mechanism has been proposed as promising therapeutic option, with venetoclax (ABT-199) being first FDA-approved inhibitor. Unfortunately, although shown remarkable results range lymphoid cancers well acute myeloid leukemia (AML), development resistance significantly reduces response rates specific subtypes. In this article, we explain role proteins apoptosis their action that justifies potential target malignancies, including chronic lymphocytic leukemia, multiple myeloma, lymphomas, but also AML. We further analyze characteristics result intrinsic or inherited inhibitors. Finally, focus on biomarkers can be used predict responses name personalized medicine, goal exploring alternative strategies overcome
Язык: Английский
Процитировано
0
Targeted Oncology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 29, 2025
Язык: Английский
Процитировано
0
Discover Oncology, Год журнала: 2025, Номер 16(1)
Опубликована: Апрель 24, 2025
This study aimed to delineate the evolving knowledge structure of programmed cell death in esophageal cancer and identify key thematic trends, influential collaborations, emerging areas for future research. A bibliometric approach was applied 2677 publications retrieved from Web Science Core Collection (2000-2024). Three complementary tools-CiteSpace, VOSviewer, bibliometrix-were employed visualize co-citation networks, detect citation bursts, map collaborative patterns among authors, institutions, countries. Inclusion criteria focused on articles reviews that addressed conjunction with apoptosis, necroptosis, pyroptosis, ferroptosis, autophagy, or related pathways. Publication outputs grew markedly, reflecting a shift early investigations basic apoptotic mechanisms broader explorations ferroptosis. China led publication volume citations, driven by substantial governmental funding large clinical cohorts. The United States Japan also contributed significantly, forming international research networks spanned Asia Europe. Leading particularly Zhengzhou University, demonstrated extensive collaborations. Journals such as Oncology Letters Reports were prominent outlets new findings, while highly cited references highlighted hypoxia, immune checkpoint blockade, gene-editing strategies. Keyword analyses revealed ascendance immuno-oncology, network pharmacology, translational applications targeting multiple regulated Bibliometric evidence underscores rapid expansion multidisciplinary integrates diverse pathways cancer. Continued leveraging advanced genomics immunologic strategies, are poised accelerate breakthroughs enable more personalized, effective therapies.
Язык: Английский
Процитировано
0
Frontiers in Pharmacology, Год журнала: 2025, Номер 16
Опубликована: Май 29, 2025
Objective To (i) quantify the prevalence of polypharmacy and clinically significant DDIs, (ii) examine their independent combined associations with ADRs, (iii) explore whether depression cognition modify these relationships among older Chinese adults cancer diagnosed cancer. A total 408 participants aged ≥60 years completed both 2011 baseline 2013 follow-up surveys, forming analytic cohort. Methods This analysis used data from China Health Retirement Longitudinal Study (CHARLS; 2011–2013). Eligible were community-dwelling who answered “yes” to CHARLS question “Has a doctor ever told you that had malignant tumour or cancer?” (variable DAOO7-4, mapped ICD-10 C00–C97). The most frequently reported sites lung, stomach, colorectal, liver breast cancers, yielding an cohort individuals. Polypharmacy (≥5 medications/day) was determined through face-to-face interviews, DDIs identified using standardized reference compendia. ADRs confirmed by self-reports corroborated medical records. Depression measured validated scales. Logistic regression models adjusted for sociodemographic clinical factors evaluate associations. Results At baseline, 36.0% polypharmacy, rising 38.0% at follow-up. Clinically increased 20.1% 23.0%, while grew 6.9% 8.1%. In models, (OR = 2.21, 95% CI 1.14–4.30) 3.28, 1.54–6.99) independently heightened ADR risk. Elevated scores also linked odds particularly women. Conclusion substantially magnify risk in cancer, further compounding vulnerability. Targeted medication management, careful DDI monitoring, attention psychosocial well-being may reduce preventable harms improve outcomes this rapidly expanding geriatric oncology population.
Язык: Английский
Процитировано
0